Biotech's Biggest Bet of the Year Just Filed to Go Public

Now there's one: nirogacestat (brand name Ogsiveo), approved in late 2023. But it comes with side effects that can be tough for young patients facing potentially years of treatment, including GI problems, skin issues, and ovarian dysfunction. That leaves a wide lane for a drug with a cleaner safety profile.

Early Results That Turned Heads

Zolucatetide is still in a Phase 1/2 trial (the early-to-mid stages of testing), but the data so far have been genuinely striking. Among desmoid tumor patients who had more than one scan on file, the objective response rate hit 80%. Every single patient who could be evaluated for response showed some degree of tumor shrinkage.

The safety profile has been remarkably clean: no severe (Grade 4 or 5) side effects related to treatment, no patients dropping out because of toxicity, and no serious GI or skin problems. For a patient population that skews young and might need long-term therapy, that matters enormously.

The FDA noticed, too. In November 2025, it granted Fast Track designation to zolucatetide for desmoid tumors, a signal that the agency sees enough promise (and enough unmet need) to speed things along.

One patient with a hereditary form of the disease saw their desmoid tumor shrink by 52.2% in diameter over 60 weeks of treatment. More than 150 patients have been dosed across the broader trial so far, with additional data readouts planned throughout 2026.

Where the Money Goes

The S-1 filing lays out a surprisingly detailed spending plan. Roughly $150 million would fund zolucatetide's push into a Phase 3 registrational trial (the final stage before seeking FDA approval) in desmoid tumors. Another $120 million goes toward testing the same drug in other conditions, including familial adenomatous polyposis (a hereditary syndrome that almost guarantees colon cancer) and liver cancer.

The remaining $130 million is earmarked for earlier-stage pipeline programs, including a protein degrader and an androgen receptor modulator. It's an ambitious menu, but Parabilis already had about $329 million in cash on hand before this filing.

Oh, and there's a cherry on top: Regeneron has agreed to buy $75 million of Parabilis stock in a concurrent private placement at a 10% discount to the IPO price. That purchase is tied to a research collaboration for "antibody-Helicon conjugates" worth up to $2.2 billion in potential milestone payments. When one of pharma's sharpest dealmakers puts real money alongside yours, it sends a message.

The IPO Market: Thawing, Not Melted

To understand why this filing matters beyond Parabilis, you need to zoom out. The biotech IPO market has been brutal. Only 10 U.S. biotech IPOs priced in all of 2025, the lowest tally in over a decade and a fraction of the more than 100 that went public during 2021's frenzy.

Q1 2026 brought signs of life: about 6 biotech IPOs in three months. Kailera Therapeutics raised a record-breaking $625 million for its obesity program. Aktis Oncology opened the year with a $318 million debut. But then activity stalled again, with BioSpace describing a subsequent six-month drought and calling it "biotech's tightest IPO window in years."

The pattern is clear: investors will open their wallets, but only for the right story. Late-stage clinical data, a clear path to revenue, and a credible management team are table stakes. Platform plays and early-stage science without proof? Good luck.

Parabilis checks many of those boxes: a well-known CEO, strong early clinical data, Fast Track designation, a Regeneron partnership, and a defined use of proceeds. If this deal prices well and trades up, it could crack the window open wider for a backlog of private biotechs waiting to go public.

The Bottom Line

Parabilis is placing a double bet. First, that its peptide platform can crack the code on targets the rest of the industry considers undruggable. Second, that public investors are finally ready to buy what biotech is selling again.

The early data in desmoid tumors are compelling; the management pedigree is elite; the Regeneron co-sign adds credibility. But this is a lot to ask from a market still nursing bruises from years of disappointing biotech debuts.

If Parabilis pulls it off, expect a parade of S-1 filings to follow. If it stumbles, that IPO window might slam shut for the rest of 2026. No pressure.

Thyroid Hormones for Depression? This Tiny Trial Just Made Big Pharma Pay Attention.

Autobahn Therapeutics just dropped Phase 2 data for a brain-targeted thyroid drug in bipolar depression, and the numbers are raising eyebrows. A tiny trial, no placebo arm, and yet the signal might be too strong to ignore.